Top 5 Papers
#1
Source: Annals of Surgical Oncology | Authors: Zhou X, Chen D, Song P, Zheng Y, et al. | Published: April 27, 2026
Score: 9/20 — Base 5 (Other journal) + Meta-analysis (+2) + Survival benefit (+2)
Meta-analysis of 8 studies involving 2,578 patients with pathologic complete response (pCR) after neoadjuvant therapy for esophageal cancer. Adequate lymph node dissection (LND) was significantly associated with improved overall survival (HR 0.70; 95% CI 0.58-0.84, p<0.001). No additional benefit was observed when harvested lymph nodes exceeded 40. Subgroup analyses revealed that adequate LND was significantly associated with superior OS in Western and adenocarcinoma-predominant populations but not in Eastern populations or squamous cell carcinoma, suggesting histology-tailored lymphadenectomy strategies.
Post angle: Even after pCR, lymph node dissection matters in esophageal cancer — but context is everything. Adenocarcinoma benefits, SCC doesn't. Personalized surgery. #Esophageal #SurgOnc #GIOnc #PrecisionMedicine
#2
Source: Annals of Surgical Oncology | Authors: D'Souza M, Andree M, Feili A, Sadr-Azodi O, Holmberg M. | Published: April 27, 2026
Score: 8/20 — Base 5 (Other journal) + Retrospective (+1) + Survival benefit (+2)
Analysis of 343 resected PDAC patients from Karolinska University Hospital. 85% recurred within 3 years, with a clear prognostic hierarchy: pulmonary metastases mOS 30 months (95% CI 27-35), other sites 20 months (95% CI 19-26), and liver 13 months (95% CI 12-16), p<0.001. Mortality risk compared to no recurrence was 7-fold for lung, 12-fold for other, and 23-fold for liver. These findings support consideration of targeted treatment strategies — including potentially aggressive local approaches — for the lung recurrence subgroup.
Post angle: Not all PDAC recurrences are equal. Lung mets: mOS 30 mo. Liver mets: 13 mo. A 23-fold vs 7-fold mortality gap. This prognostic hierarchy should guide treatment intensity. #PDAC #PancreaticCancer #SurgOnc #GIOnc
#3
Source: World Journal of Surgical Oncology | Authors: Aldarwish M, Hoelzen JP, El-Sourani N, et al. | Published: April 25, 2026
Score: 8/20 — Base 5 (Other journal) + Retrospective (+1) + Survival benefit (+2)
Retrospective analysis of 145 patients undergoing total gastrectomy for gastric cancer (2012-2023). Completion of the perioperative chemotherapy sequence was independently associated with markedly improved 1-year OS compared to neoadjuvant alone (HR 0.20; 95% CI 0.08-0.50, p=0.001), remaining significant in 60-day landmark analysis. Critically, 55.3% of patients who started neoadjuvant chemotherapy did not proceed to the adjuvant phase, primarily due to patient refusal or medical contraindications. Poorer tumor regression grade showed a prognostic trend (HR 1.60, p=0.059).
Post angle: HR 0.20 — completing perioperative chemo after gastrectomy is an 80% mortality reduction at 1 year. Yet 55% of patients never finish. This is a quality gap we can close. #GastricCancer #SurgOnc #GIOnc #QualityOfCare
#4
Source: Journal of Gastroenterology and Hepatology | Authors: Kuan TC, Wu CY, Chen CC, Giovannucci E, Liu JJ. | Published: April 26, 2026
Score: 6/20 — Base 5 (Other journal) + Retrospective/real-world (+1)
Nationwide study of 92,365 CRC patients from the Taiwan Cancer Registry (2002-2015). EOCRC patients (<50 years) presented with more advanced staging but demonstrated slightly better 5-year CRC-specific survival than LOCRC after adjusting for sex and tumor characteristics — across all CRC sites. EOCRC patients had more females, more current alcohol/cigarette users, and less right-sided disease. Notably, female sex and treatment delay <30 days were associated with improved survival in LOCRC but not EOCRC, suggesting distinct biology. Underweight BMI was a risk factor only in LOCRC.
Post angle: 92K patients confirm: early-onset CRC is a different disease. More advanced at diagnosis yet better cancer-specific survival. The biology differs — we need age-specific screening & treatment strategies. #EOCRC #CRC #GIOnc
#5
Source: Cancer Science | Authors: Deng C, Zhou Y, Song S, Liu H, et al. | Published: April 26, 2026
Score: 6/20 — Base 5 (Other journal) + Biomarker-guided/precision (+1)
SLC1A3, the primary aspartate transporter, is significantly overexpressed in CRC and associated with poor prognosis. This study reveals a dual mechanism: SLC1A3 enhances CRC cell proliferation, invasion, and migration through the DAG/PKC/MDM2 signaling axis (suppressing p53), while simultaneously inducing immunosuppressive M2 macrophage polarization via upregulation of IL17c and CSF2. This dual tumor-intrinsic and immune-modulatory role makes SLC1A3 a promising therapeutic target that could simultaneously address tumor growth and immune evasion.
Post angle: One transporter, two mechanisms: SLC1A3 drives CRC growth via MDM2-p53 AND reshapes the immune microenvironment via M2 macrophage polarization. A dual-target opportunity. #CRC #Immunology #PrecisionMedicine #GIOnc
Additional Papers of Interest
-
ASCO Educational Book — Comprehensive review of KRAS G12C combos, BRAF strategies, ADCs, bispecific antibodies, DDR inhibitors, and TME-modulating agents reshaping precision CRC oncology (Lenz HJ et al.)
-
J Gastroenterol Hepatol — GBD 2021 + GLOBOCAN 2022 analysis: CRC ranks highest ASIR across Asia-Pacific; Mongolia disproportionately burdened by esophageal, gastric, and liver cancers
-
J Translational Medicine — METTL3 stabilizes MALAT1 via m6A modification, activating NF-kB through IkBa degradation and p65 nuclear translocation; METTL3 inhibitor suppresses xenograft growth
-
Scientific Reports — Histotripsy dose impacts cellular damage and treatment outcomes in HCC; dose optimization enables abscopal immune effects
-
Molecular Diversity — TCM-derived rubimaillin shows IC50 1.10 uM in MIA PaCa-2 cells, reduces KRAS protein, modulates p53/BCL2, inhibits migration in PDAC cell lines
Back to all digests